Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE The synthetic drug ebselen can bind to both the catalytic region and a previously unknown distant site on the SARS-CoV-2 virus’ main protease, according to a molecular simulation analysis of the drug’s interactions with this enzyme. The results...
Tag: <span>Cholesterol Drug’s</span>
Post
Out-of-pocket costs often keep pricey new cholesterol drugs out of reach, study finds
Access to powerful new cholesterol-lowering drugs is so tightly controlled and patients’ out-of-pocket costs are so high that fewer than a third of people whose doctors prescribe the drugs get them, a new study found. While highly effective, the new drugs cost as much as $14,000 annually, leading some insurers and pharmacy benefit managers to require doctors...
Post
Pricey New Cholesterol Drug’s Effect On Heart Disease Is More Modest Than Hoped
Another cardiology meeting, another big prevention trial – and questions abound. People at risk for cardiovascular disease will be wondering about the implications for them. So are the doctors. New trials take some time to digest – and yet our news cycle wants quick, succinct answers. Sometimes it is not an easy call. So here...